Top ten biotechnologies for improving health in developing countries

Nature Genetics

Volumn 32, Issue 2, 2002, Pages 229-232

  Daar, Abdallah S ^a   Thorsteinsdóttir, Halla ^a   Martin, Douglas K ^a   Smith, Alyna C ^a   Nast, Shauna ^a   Singer, Peter A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; DEVELOPING COUNTRY; GENOMICS; HEALTH CARE; HUMAN; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW;

BIOTECHNOLOGY; COMMUNICABLE DISEASES; DEVELOPING COUNTRIES; DRUG DELIVERY SYSTEMS; FORECASTING; VACCINES, SYNTHETIC; WORLD HEALTH;

EID: 0036788654     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1002-229     Document Type: Review

References (31)

1. Global Forum for Health Research. The 10/90 Report on Health Research 2000. (Global Forum for Health Research, Geneva, 2000).
2. World Health Organization. Genomics and World Health (Report of the Advisory Committee on Health Research) (World Health Organization, Geneva, 2002)
3. Adler, M. & Ziglio, E. Gazing into the Oracle: The Delphi Method and its Implications for Social Policy and Public Health (Jessica Kingsley, London, 1996).
4. Program in Applied Ethics and Biotechnology & Canadian Program in Genomics and Global Health, University of Toronto Joint Centre for Bioethics. Top 10 Biotechnologies for Improving Health in Developing Countries (Univ. of Toronto Press, in press).
5. Harris, E. A Low Cost Approach to PCR: Appropriate Technology Transfer of Biomolecular Techniques (ed. Kadir, N.) (Oxford Univ. Press, New York, 1998).
6. Palmer, C.J. et al. Evaluation of the OptiMAL test for rapid diagnosis of Plasmodium vivax and Plasmodium falciparum malaria. J. Clin. Microbiol. 36, 203-206 (1998).
7. Aidoo, S. et al. Suitability of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus in Ghana, West Africa. J. Clin. Microbiol. 39, 2572-2575 (2001).
8. Panteleeff, D.D. et al. Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J. Clin Microbiol 37, 350-353 (1999).
9. Beck, A.I. et al. Simple, sensitive, and specific detection of human immunodeficiency virus type 1 subtype B DNA in dried blood samples for diagnosis in infants in the field. J. Clin. Microbiol. 39, 29-33 (2001).
10. Bojang, K.A. et al. Efficacy of RTS, SIAS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927-1934 (2001).
11. Lee, E.A. et al. induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect. Immun. 70, 1417-1421 (2002).
12. Abraham, P. et al. Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine 17, 1125-1129 (1999).
13. Belshe, R.B. et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher-and lower-risk volunteers. J. Infect. Dis. 183, 1343-1352 (2001).
14. Kane, A., Lloyd, J., Zaffran, M., Simonsen, L. & Kane, M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull. World Health Organ. 77, 801-807 (1999).
15. World Health Organization. Fact Sheet 169: Global Alliance for Vaccines and Immunization (World Health Organization, Geneva, 2001; http://www.who.int/inf-fs/en/factl69.html).
16. Jha, P. et al. Improving the health of the global poor. Science 295, 2036-2039 (2002).
17. Langridge, W.H.R. Edible vaccines. Sci. Am. 283, 66-71 (2000).
18. Jodar, L. et al. Ensuring vaccine safety in immunization programmes - a WHO perspective. Vaccine 19, 1594-1905 (2001).
19. World Health Organization. Fact Sheet 106: Noncommunicable Diseases: WHO Experts Warn Against Inadequate Prevention, Particularly in Developing Countries (World Health Organization, Geneva, 1996; http://www.who.int/inf-fs/en/fact106.html).
20. Boyd, M.R. et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41, 1521-1530 (1997).
21. Kelley, B.S., Chang, L.C. & Bewley, C.A. Engineering an obligate domain-swapped dimer of cyanovirin-N with enhanced anti-HIV activity. J. Am. Chem. Soc. 124, 3210-3211 (2002).
22. United States Environmental Protection Agency. Citizen's Guide to Bioremediation (U.S. Environmental Protection Agency, Washington, DC, 2001).
23. Butler, D. Bioinformatics to be nurtured online. Nature 411, 513 (2001).
24. Benson, D.A. et al. GenBank. Nucleic Acids Res. 28, 15-18 (2001).
25. Gold, R.E., Castle, D., Cloutier, L.M., Daar, A.S. & Smith, P.J Needed: models of biotechnology intellectual property. Trends Biotech. 20, 327-329 (2002).
26. Normile, D. Monsanto donates its share of Golden Rice. Science 289, 843-845 (2000).
27. Jomaa, H. et al., Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285, 1573-1576 (1999).
28. Wiesner, J. et al. Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-Acylamino-3-benzoylphenyl)-4-propoxycinnaic acid amides. Bioorg. Med. Chem. Lett. 25, 543-545 (2002).
29. United Nations Development Programme. Human Development Report 2001: Making New Technologies Work for Human Development (Oxford Univ. Press, New York, 2001).
30. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development (Report of the Commission on Macroeconomics and Health) (World Health Organization, Geneva, 2001).
31. Martin, B.R. Foresight in science and technology. Technol. Anal. Strateg. Manage. 7, 139-168 (1995).